Clinical Trial

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time of resection.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2019-07-08; most recent amendment 2025-11-05.
Status change: Recruiting → Active, Not Recruiting 2024-11-04
Status change: Active, Not Recruiting → Recruiting 2020-09-02
Status change: Recruiting → Active, Not Recruiting 2020-04-03
Status change: Not Yet Recruiting → Recruiting 2020-02-26
Trial Details
NCT Number NCT04013854
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Melanoma Stage III, Melanoma
Enrollment 67 participants
Start Date 2020-01-01
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-11-06